Genetic Risk of Cardiovascular Disease Is Associated with Macular Ganglion Cell-Inner Plexiform Layer Thinning in an Early Glaucoma Cohort.
ANOVA, analysis of variance
ANZRAG, Australia New Zealand Registry of Advanced Glaucoma
CI, confidence interval
Cardiovascular disease
DDLS, Disc Damage Likelihood Scale
GCIPL, ganglion cell–inner plexiform layer
Glaucoma
HVF, Humphrey Visual Field
IOP, intraocular pressure
Macular GCIPL
OR, odds ratio
POAG, primary open-angle glaucoma
PROGRESSA, Progression Risk of Glaucoma: Relevant SNPs with Significant Association
Paracentral visual field
Retinal thinning
SNP, single nucleotide polymorphism
VCDR, vertical cup-to-disc ratio
pRNFL, peripapillary retinal nerve fiber layer
Journal
Ophthalmology science
ISSN: 2666-9145
Titre abrégé: Ophthalmol Sci
Pays: Netherlands
ID NLM: 9918230896206676
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
28
09
2021
revised:
05
11
2021
accepted:
16
12
2021
entrez:
17
10
2022
pubmed:
18
10
2022
medline:
18
10
2022
Statut:
epublish
Résumé
To evaluate the association between genetic risk for cardiovascular disease and retinal thinning in early glaucoma. Prospective, observational genetic association study. Multicohort study combining a cohort of patients with suspect and early manifest primary open-angle glaucoma (POAG), a cohort of patients with perimetric POAG, and an external normative control cohort. A cardiovascular disease genetic risk score was calculated for 828 participants from the Progression Risk of Glaucoma: Relevant SNPs [single nucleotide polymorphisms] with Significant Association (PROGRESSA) study. Participants were characterized as showing either predominantly macular ganglion cell-inner plexiform layer (GCIPL), predominantly peripapillary retinal nerve fiber layer (pRNFL) or equivalent macular GCIPL and pRNFL spectral-domain OCT thinning. The cardiovascular disease genetic risk scores for these groups were compared to an internal reference group of stable suspected glaucoma and of an external normative population. Replication was undertaken by comparing the phenotypes of participants from the Australia New Zealand Registry of Advanced Glaucoma (ANZRAG) with the normative control group. Spectral-domain OCT and Humphrey Visual Field (HVF) change. After accounting for age, sex, and intraocular pressure (IOP), participants with predominantly macular GCIPL thinning showed a higher cardiovascular disease genetic risk score than reference participants (odds ratio [OR], 1.76/standard deviation [SD]; 95% confidence interval [CI], 1.18-2.62; This study highlighted the relationship between cardiovascular disease and retinal thinning in suspect and manifest glaucoma cases.
Identifiants
pubmed: 36246177
doi: 10.1016/j.xops.2021.100108
pii: S2666-9145(21)00106-8
pmc: PMC9559075
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100108Informations de copyright
© 2021 by the American Academy of Ophthalmology.
Références
Ophthalmology. 2019 Aug;126(8):1119-1130
pubmed: 30910584
Invest Ophthalmol Vis Sci. 2015 Apr;56(4):2439-48
pubmed: 25758813
Nat Rev Genet. 2018 Sep;19(9):566-580
pubmed: 29872216
J Diabetes Complications. 2013 Nov-Dec;27(6):642-8
pubmed: 24055326
Invest Ophthalmol Vis Sci. 2006 Dec;47(12):5171-6
pubmed: 17122099
Retina. 2019 Sep;39(9):1810-1818
pubmed: 29757807
Ophthalmology. 2021 Mar;128(3):393-400
pubmed: 32739337
Ophthalmology. 2021 Jan;128(1):58-69
pubmed: 32730956
Am J Ophthalmol. 2014 Sep;158(3):615-27.e9
pubmed: 24879946
Ophthalmology. 2019 Apr;126(4):497-510
pubmed: 30114417
Mol Genet Genomic Med. 2019 Nov;7(11):e955
pubmed: 31496134
Ophthalmology. 2012 Apr;119(4):731-7
pubmed: 22264886
J Glaucoma. 2012 Aug;21(6):372-8
pubmed: 21430549
Invest Ophthalmol Vis Sci. 2012 Oct 17;53(11):7194-200
pubmed: 22997288
PLoS One. 2014 Sep 25;9(9):e108226
pubmed: 25254373
Science. 2007 Jun 8;316(5830):1488-91
pubmed: 17478681
Am J Hypertens. 2015 Sep;28(9):1077-82
pubmed: 25767134
Clin Exp Ophthalmol. 2012 May-Jun;40(4):341-9
pubmed: 22356435
Invest Ophthalmol Vis Sci. 2014 Apr 21;55(4):2557-63
pubmed: 24692126
Nat Genet. 2011 Jun;43(6):574-8
pubmed: 21532571
Nat Genet. 2020 Feb;52(2):160-166
pubmed: 31959993
Prog Retin Eye Res. 2013 Jan;32:1-21
pubmed: 22995953
Trends Genet. 2013 Feb;29(2):66-73
pubmed: 23140989
Invest Ophthalmol Vis Sci. 2019 Feb 28;60(3):M20-M30
pubmed: 30817826
J Glaucoma. 2004 Aug;13(4):319-26
pubmed: 15226661
Int J Epidemiol. 2012 Aug;41(4):929-929i
pubmed: 22933644
Invest Ophthalmol Vis Sci. 2013 Sep 11;54(9):6150-7
pubmed: 23963166
Hum Mol Genet. 2014 Sep 15;23(R1):R89-98
pubmed: 25064373
J Am Coll Cardiol. 2018 Oct 16;72(16):1883-1893
pubmed: 30309464
Proc Natl Acad Sci U S A. 2017 Oct 31;114(44):11727-11732
pubmed: 29078306
Med J Aust. 2014 May 5;200(8):454, 456
pubmed: 24794600
Am J Hum Genet. 2007 Sep;81(3):559-75
pubmed: 17701901
Ophthalmology. 2011 Sep;118(9):1782-9
pubmed: 21665283
Invest Ophthalmol Vis Sci. 2019 Mar 1;60(4):1028-1043
pubmed: 30897618
Am J Ophthalmol. 2002 Jun;133(6):758-63
pubmed: 12036666
Lancet Digit Health. 2019 Jul;1(3):e101-e103
pubmed: 33323255
Acta Ophthalmol. 2022 Mar;100(2):148-158
pubmed: 33506616
Clin Exp Ophthalmol. 2012 Aug;40(6):569-75
pubmed: 22171965
Trans Am Ophthalmol Soc. 2002;100:181-5; discussion 185-6
pubmed: 12545692
Nat Commun. 2021 Feb 24;12(1):1258
pubmed: 33627673
Prog Retin Eye Res. 2002 Jul;21(4):359-93
pubmed: 12150988
Nat Genet. 2018 Aug;50(8):1067-1071
pubmed: 30054594